Covered recipient · General Payments record
CARL DANZIG
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$150,110.30
150 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $78,900.00 | 13 |
| Consulting Fee | $57,347.91 | 49 |
| Travel and Lodging | $9,636.96 | 27 |
| Food and Beverage | $4,225.43 | 61 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $91,955.04 | 61 |
| Ocular Therapeutix, Inc. | $36,074.92 | 46 |
| Genentech USA, Inc. | $9,196.41 | 11 |
| Astellas Pharma Global Development | $5,155.40 | 5 |
| Apellis Pharmaceuticals, Inc. | $3,343.69 | 6 |
| Genentech, Inc. | $1,708.49 | 3 |
| ABBVIE INC. | $1,227.10 | 3 |
| Samsung Bioepis Co., Ltd. | $712.50 | 1 |
| Harrow Eye, LLC | $342.83 | 4 |
| Regeneron Healthcare Solutions, Inc. | $146.02 | 2 |
| ANI Pharmaceuticals, Inc. | $108.93 | 3 |
| Regeneron Pharmaceuticals, Inc. | $92.73 | 3 |
| BIOTISSUE HOLDINGS INC. | $46.24 | 2 |
Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
CARL DANZIG
NPI 1619137320 · CMS profile ID 209355
Allopathic & Osteopathic Physicians / Ophthalmology
POMPANO BEACH, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- CARL DANZIG, NPI 1619137320, CMS profile ID 209355. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). CARL DANZIG, NPI 1619137320, CMS profile ID 209355. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- CARL DANZIG, NPI 1619137320, CMS profile ID 209355, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–150 of 150 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1619137320?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
150 matching records · $150,110.30 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 150.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix, Inc. | $1,000.00 | 07/15/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226754 | CMS |
| Genentech, Inc. | $840.00 | 07/02/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211500659 | CMS |
| Genentech, Inc. | $840.00 | 07/02/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211500661 | CMS |
| Ocular Therapeutix, Inc. | $2,500.00 | 06/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226750 | CMS |
| ABBVIE INC. | $59.72 | 06/20/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201725704 | CMS |
| Ocular Therapeutix, Inc. | $1,833.33 | 06/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226756 | CMS |
| Ocular Therapeutix, Inc. | $2,000.00 | 06/19/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226732 | CMS |
| Ocular Therapeutix, Inc. | $242.12 | 06/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226820 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 06/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226798 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 06/17/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226742 | CMS |
| Astellas Pharma US Inc | $900.00 | 06/12/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238709464 | CMS |
| Astellas Pharma US Inc | $7,200.00 | 06/07/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238709542 | CMS |
| Astellas Pharma US Inc | $292.60 | 06/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238709726 | CMS |
| Astellas Pharma US Inc | $118.25 | 06/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238709730 | CMS |
| Astellas Pharma US Inc | $446.00 | 06/07/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1238709734 | CMS |
| Astellas Pharma Global Development | $2,769.00 | 06/06/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1234125942 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 05/29/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226734 | CMS |
| ANI Pharmaceuticals, Inc. | $22.58 | 05/28/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248656528 | CMS |
| Ocular Therapeutix, Inc. | $18.10 | 05/13/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226810 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 05/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226782 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 05/10/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226748 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 05/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226796 | CMS |
| Ocular Therapeutix, Inc. | $29.43 | 05/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226812 | CMS |
| Genentech, Inc. | $28.49 | 05/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211500657 | CMS |
| Regeneron Pharmaceuticals, Inc. | $18.30 | 05/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1213237059 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 05/05/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226738 | CMS |
| Ocular Therapeutix, Inc. | $117.18 | 05/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226818 | CMS |
| Genentech USA, Inc. | $12.39 | 05/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211500645 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 04/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226740 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 04/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226774 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 04/24/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226788 | CMS |
| Apellis Pharmaceuticals, Inc. | $30.19 | 04/16/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253191026 | CMS |
| Ocular Therapeutix, Inc. | $2,000.00 | 04/04/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226758 | CMS |
| Ocular Therapeutix, Inc. | $110.92 | 04/02/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226814 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 04/01/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226736 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 03/18/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226772 | CMS |
| Apellis Pharmaceuticals, Inc. | $25.41 | 03/12/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1253191024 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 03/03/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226790 | CMS |
| Ocular Therapeutix, Inc. | $2,500.00 | 02/22/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226744 | CMS |
| Ocular Therapeutix, Inc. | $1,000.00 | 02/07/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226800 | CMS |
| Ocular Therapeutix, Inc. | $3.52 | 02/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226806 | CMS |
| Ocular Therapeutix, Inc. | $16.03 | 02/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226808 | CMS |
| ANI Pharmaceuticals, Inc. | $16.05 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248593171 | CMS |
| ANI Pharmaceuticals, Inc. | $70.30 | 02/05/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248595196 | CMS |
| Regeneron Healthcare Solutions, Inc. | $120.65 | 01/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1212898745 | CMS |
| Ocular Therapeutix, Inc. | $1,500.00 | 01/27/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226778 | CMS |
| Ocular Therapeutix, Inc. | $500.00 | 01/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226762 | CMS |
| Ocular Therapeutix, Inc. | $250.00 | 01/20/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1250226784 | CMS |
| Samsung Bioepis Co., Ltd. | $712.50 | 01/16/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1219721999 | CMS |
| ABBVIE INC. | $142.38 | 01/08/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201725702 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $12,259.42 | 5 |
| PY2025 | Principal investigator | $454,878.76 | 200 |
| PY2024 | Recipient | $11,426.05 | 5 |
| PY2024 | Principal investigator | $540,270.42 | 147 |
| PY2023 | Recipient | $2,329.88 | 4 |
| PY2023 | Principal investigator | $527,421.56 | 174 |
| PY2022 | Principal investigator | $623,708.70 | 89 |
| PY2021 | Recipient | $9,310.75 | 4 |
| PY2021 | Principal investigator | $606,141.71 | 70 |
| PY2020 | Recipient | $10,996.39 | 6 |
| PY2020 | Principal investigator | $1,198,521.25 | 30 |
| PY2019 | Principal investigator | $862,840.66 | 50 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
205 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,917.00 | 12/31/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241181 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $275.00 | 12/31/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241183 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/31/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241185 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/31/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241187 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/31/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241189 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/29/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241179 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $15,526.80 | 12/24/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241175 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,206.50 | 12/24/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241177 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,258.00 | 12/22/2025 | Non-covered Recipient Entity William J. Rand MDPA | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220813671 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/17/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241167 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/17/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241169 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/17/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241171 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/17/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241173 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,244.50 | 12/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241157 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241159 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241161 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241163 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241165 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/05/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241155 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $280.00 | 12/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241152 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652634 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $275.00 | 12/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241146 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 12/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241148 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,181.40 | 12/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241150 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 11/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241134 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 11/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241136 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $445.00 | 11/11/2025 | Non-covered Recipient Entity William J. Rand MDPA | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220813669 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $857.25 | 11/05/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409712 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $135.00 | 11/05/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225409756 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652632 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,014.00 | 10/17/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241130 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $200.00 | 10/14/2025 | Non-covered Recipient Entity Rand Eye Institute | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250236499 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,875.00 | 10/10/2025 | Non-covered Recipient Entity William J. Rand MDPA | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220813667 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $21,193.20 | 10/08/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241124 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 10/08/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241126 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,917.00 | 10/08/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241128 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652630 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.00 | 09/26/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241122 |
| Recipient | F. Hoffmann-La Roche AG | $644.00 | 09/19/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211535025 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $398.00 | 09/10/2025 | Non-covered Recipient Entity William J. Rand MDPA | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220813663 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $680.00 | 09/10/2025 | Non-covered Recipient Entity William J. Rand MDPA | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220813665 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,774.06 | 09/10/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241120 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $135.00 | 09/08/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410514 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $300.00 | 09/08/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410750 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $100.00 | 09/08/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411210 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $97.20 | 09/08/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411406 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $496.40 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241096 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.40 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241098 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.40 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241100 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.40 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241102 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.40 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241104 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241106 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $125.00 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241108 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $496.40 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241110 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241112 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,640.00 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241114 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,840.00 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241116 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,434.00 | 09/03/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241118 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652628 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,495.00 | 08/29/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241092 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $7,465.50 | 08/29/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241094 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,244.50 | 08/27/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241090 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,515.00 | 08/20/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241088 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,516.00 | 08/18/2025 | Non-covered Recipient Entity William J. Rand MDPA | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220813661 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $175.00 | 08/15/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241084 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $175.00 | 08/15/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241086 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,120.00 | 08/13/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241082 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $10,371.60 | 08/08/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241080 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,395.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241060 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,615.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241062 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241064 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241066 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,564.50 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241068 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $175.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241070 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,295.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241072 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241074 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241076 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.40 | 08/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241078 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652626 |
| Recipient | F. Hoffmann-La Roche AG | $685.71 | 08/01/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211535029 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,634.40 | 08/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241053 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.40 | 08/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241055 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,483.90 | 08/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241058 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,470.00 | 07/30/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241051 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $6,440.00 | 07/25/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241045 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $16,014.60 | 07/25/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241047 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $3,774.06 | 07/25/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241049 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,840.00 | 07/23/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241039 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.40 | 07/23/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241041 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $225.00 | 07/23/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241043 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/18/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241035 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/18/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241037 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $425.00 | 07/16/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241033 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241021 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241023 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241025 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241027 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241029 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241031 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $14,931.00 | 07/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241009 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241011 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241013 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241015 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 07/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241017 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $475.00 | 07/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652624 |
| Recipient | Ocular Therapeutix, Inc. | $9,600.00 | 06/30/2025 | Covered Recipient Physician | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250229187 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 06/18/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685404 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $135.00 | 06/18/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241001 |
| Recipient | F. Hoffmann-La Roche AG | $685.71 | 06/16/2025 | Covered Recipient Physician | Association of early macular leakage resolution with extended treatment intervals in patients with RVO: A BALATON/COMINO post hoc analysis | No dispute reported | 06/30/2026 | 1211535033 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $740.00 | 06/13/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240997 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $4,131.90 | 06/13/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240999 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,797.00 | 06/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240989 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 06/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240991 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $13,757.40 | 06/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240993 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,840.00 | 06/11/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240995 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $2,427.00 | 06/06/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240987 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,400.00 | 06/02/2025 | Non-covered Recipient Entity William J. Rand MDPA | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220813659 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652610 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,873.15 | 05/28/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407746 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 05/28/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240979 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 05/28/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240981 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 05/28/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240983 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 05/28/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 05/27/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 05/27/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652614 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 05/27/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652616 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $85.84 | 05/27/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652618 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.00 | 05/27/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.83 | 05/27/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652622 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $49,127.40 | 05/16/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240975 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,634.00 | 05/16/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240977 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $31,609.80 | 05/14/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240973 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $3,000.00 | 05/02/2025 | Non-covered Recipient Entity RAND EYE INSTITUTE, INC | ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study | No dispute reported | 06/30/2026 | 1190308084 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652608 |
| Principal investigator 1 | Genentech, Inc. | $14,522.00 | 05/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685402 |
| Principal investigator 1 | Genentech, Inc. | $585.00 | 05/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685406 |
| Principal investigator 1 | Genentech, Inc. | $159.00 | 05/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685408 |
| Principal investigator 1 | Genentech, Inc. | $273.00 | 05/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685410 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 05/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685412 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 05/01/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685414 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $314.00 | 04/16/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240971 |
| Recipient | F. Hoffmann-La Roche AG | $644.00 | 04/14/2025 | Covered Recipient Physician | A PHASE III STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION | No dispute reported | 06/30/2026 | 1211535021 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 04/09/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240967 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 04/09/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240969 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $97.20 | 04/02/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404850 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $100.00 | 04/02/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405554 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $135.00 | 04/02/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406966 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 04/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240963 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 04/02/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 04/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652600 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 04/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652602 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 04/01/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652586 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652588 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652590 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $85.84 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.44 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652594 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.00 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652596 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.83 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220652598 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | Phase II PAFRa in GA | No dispute reported | 06/30/2026 | 1220652636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $319.68 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | Phase II PAFRa in GA | No dispute reported | 06/30/2026 | 1220652638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | Phase II PAFRa in GA | No dispute reported | 06/30/2026 | 1220652640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $7.00 | 03/25/2025 | Non-covered Recipient Entity Rand Eye Institute | Phase II PAFRa in GA | No dispute reported | 06/30/2026 | 1220652642 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 03/14/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241007 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $275.00 | 03/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241003 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $9,651.60 | 03/12/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250241005 |
| Principal investigator 1 | Genentech, Inc. | $130.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685370 |
| Principal investigator 1 | Genentech, Inc. | $950.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685372 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685374 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685378 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685386 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685388 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685392 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685394 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685396 |
| Principal investigator 1 | Genentech, Inc. | $1,306.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685398 |
| Principal investigator 1 | Genentech, Inc. | $65.00 | 03/07/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685400 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 02/28/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240961 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,350.70 | 02/27/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406380 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,873.15 | 02/27/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406382 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $10,475.45 | 02/26/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) | No dispute reported | 06/30/2026 | 1185555818 |
| Principal investigator 1 | Genentech, Inc. | $4,170.00 | 02/26/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685380 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $275.00 | 02/19/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240955 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $239.05 | 02/12/2025 | Non-covered Recipient Entity Rand Eye Institute | A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. | No dispute reported | 06/30/2026 | 1220794335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,500.00 | 02/07/2025 | Non-covered Recipient Entity RAND EYE INSTITUTION | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184152840 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,800.00 | 02/07/2025 | Non-covered Recipient Entity RAND EYE INSTITUTION | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184152842 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,838.00 | 02/07/2025 | Non-covered Recipient Entity RAND EYE INSTITUTION | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184152844 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,500.00 | 02/07/2025 | Non-covered Recipient Entity RAND EYE INSTITUTION | A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1184152846 |
| Principal investigator 1 | Genentech, Inc. | $5,828.00 | 02/05/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685382 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,350.70 | 01/30/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404060 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,350.70 | 01/30/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404469 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,350.70 | 01/30/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406378 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 01/24/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240949 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $75.00 | 01/24/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240951 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,444.50 | 01/24/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240953 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $1,395.00 | 01/24/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240957 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $24,885.00 | 01/24/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240959 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 01/22/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685376 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 01/22/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685384 |
| Principal investigator 1 | Genentech, Inc. | $68.00 | 01/22/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA 2 | iAMD Observational Study | No dispute reported | 06/30/2026 | 1211685390 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $135.00 | 01/15/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405924 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $275.00 | 01/13/2025 | Non-covered Recipient Entity WILLIAM J RAND MD PA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250240947 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $135.00 | 01/09/2025 | Non-covered Recipient Entity Rand Eye Institute | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405944 |